Litigation Details for AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2021)

AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2021)

Docket		Date Filed	2021-04-08
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	AMNEAL PHARMACEUTICALS LLC
Patents	10,695,329; 10,799,453; 10,894,039; 10,952,998
Attorneys	ARNOLD B. CALMANN
Firms	Stone Conroy LLC
Link to Docket	External link to docket

Details for AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC (D.N.J. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-08				External link to document

AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC (3:21-cv-08717): Litigation Summary, Claims at Issue, and Practical IP Risk Assessment

Last updated: July 24, 2026

AZURITY PHARMACEUTICALS, INC. v. AMNEAL PHARMACEUTICALS LLC, No. 3:21-cv-08717, is a patent infringement action tied to FDA/ANDA generic development under the Hatch-Waxman framework. The case posture turns on which Orange Book-listed patents were asserted, whether Amneal’s ANDA triggered Paragraph IV litigation, and what remedies AZURITY sought (injunction and/or damages) against Amneal’s proposed launch.

Litigation value for decision-makers: the case is an evidence funnel for (1) enforceability and claim construction, (2) whether Amneal’s proposed product infringes the asserted claims, and (3) whether any asserted patents are invalid for statutory or obviousness-type reasons. For generic entry planning, the practical question is which specific asserted patents control exclusivity loss and launch timing, and whether settlement or non-final rulings shift the launch calendar.

What patents did AZURITY assert against AMNEAL in 3:21-cv-08717, and what claims were at issue?

Answer (case mechanics): In a Hatch-Waxman infringement suit filed after an ANDA Paragraph IV notice, AZURITY’s operative complaint typically identifies one or more Orange Book-listed patents as asserted against Amneal’s generic product. The “claims at issue” are the infringed claims of those asserted patents under 35 U.S.C. §271(e)(2), scoped to the ANDA product design (drug substance, formulation, dosage form, and labeling/indications if method-of-use is asserted).

How to map “asserted patents” to launch risk

• If the asserted patents are drug substance patents, the infringement analysis often focuses on chemical structure equivalence and composition coverage.
• If the asserted patents are formulation patents, focus is on excipients, crystal form/polymorph, dissolution profile, and manufacturing parameters tied to claim limitations.
• If the asserted patents are method-of-use patents, the infringement inquiry tracks proposed labeling and whether the ANDA’s indicated use falls within the method claim.

What to do with this in practice

• Build a claim chart for each asserted patent to map each limitation to Amneal’s ANDA product description and any publicly available formulation/manufacturing details.
• Track whether the court addressed claim construction early, because claim construction outcomes often determine whether non-infringement motions or validity challenges can succeed.

Without the complaint text, the Orange Book list for the relevant NDA, and the docket’s dispositive order history, the specific patent numbers and claim sets cannot be stated from the provided case identifier alone.

Which patent types usually dominate AZURITY vs. AMNEAL-style ANDA disputes?

• Composition-of-matter (active ingredient or salt/solvate form)
• Formulation (tablet/capsule composition, coatings, granulation, dissolution characteristics)
• Process/manufacturing method
• Method-of-use (labeling/therapeutic indication-driven)

When does AZURITY vs. AMNEAL 3:21-cv-08717 resolve exclusivity, and what does it mean for generic launch dates?

Answer (exclusive entry logic): In Hatch-Waxman litigation, resolution timing drives whether Amneal can launch before patent expiration and whether any 30-month stay lifts. The practical timeline has three key decision points:

1. Filing date relative to ANDA notice: determines when the 30-month stay attaches (if applicable).
2. Final court judgment (infringement/non-infringement and validity) or settlement: determines whether Amneal’s FDA approval becomes actionable for commercial launch.
3. Any injunction scope: if infringement is found and the court issues an injunction, Amneal’s launch is typically blocked until design-around or patent expiry.

Key outcome states that matter commercially

• No infringement finding for Amneal: opens a path to launch once FDA approval and remaining stays are cleared.
• Invalidity finding: accelerates launch timing for that product.
• Judgment for AZURITY with surviving patents: pushes launch to the later of remaining exclusivity or the end of the injunction period, unless a settlement provides carve-outs.
• Settlement: often includes a “trigger” date tied to patent expiration, dismissal terms, and sometimes design-around or “carve-out” language.

How the 30-month stay interacts with this litigation

If the suit was timely filed in response to a Paragraph IV notice, a 30-month stay can delay FDA approval action. Even if FDA approval occurs, the stay and injunction determine whether launch can occur legally. Commercial planning should treat the case docket dates as calendar drivers.

The case identifier alone does not provide the docket’s dispositive/settlement milestones or any court-ordered launch authorization dates.

What is the Orange Book status of the AZURITY product(s) challenged in 3:21-cv-08717?

Answer (what Orange Book status controls): Orange Book listing drives:

• which patents trigger Paragraph IV litigation,
• which patents extend exclusivity, and
• the effective “patent wall” controlling launch.

In a typical ANDA dispute, Orange Book-listed patents are categorized by type (drug substance, drug product, method of use). The “Orange Book status” relevant to Amneal’s risk is:

• which patents are listed as unexpired at the ANDA filing date,
• which patents AZURITY asserted in court, and
• whether the asserted patents expire before or after the 30-month stay window.

Orange Book listing details depend on the specific NDA/active ingredient and Orange Book entry for the AZURITY-branded product, which is not provided in the prompt. The exact status cannot be stated without the product identification from docket filings or FDA records.

How strong is AZURITY’s patent estate versus AMNEAL’s non-infringement and invalidity defenses in 3:21-cv-08717?

Answer (evaluation framework): Strength is measured by how the case resolves claim construction, obviousness/novelty, and infringement mapping against Amneal’s proposed ANDA product.

• If the court adopts AZURITY’s constructions and narrows claim scope away from Amneal’s design, infringement risk rises.
• If the court finds key claim limitations are not met by Amneal’s product, infringement risk drops.
• If invalidity is sustained, AZURITY’s enforceable rights diminish even if infringement could otherwise be shown.

Litigation signals that typically change “strength” early

• early claim construction order,
• denial/grant of summary judgment motions,
• Daubert rulings on expert testimony affecting obviousness,
• rulings on written description/enablement if relevant to software/process elements,
• whether the court resolves inequitable conduct allegations (rarely in a way that changes claim validity absent specific findings).

The prompt provides no docket orders or claim-construction/summary judgment outcomes, so the litigation “strength” cannot be tied to a specific ruling.

What Paragraph IV and ANDA arguments were central to the case?

Answer (typical Paragraph IV/ANDA arguments): In an ANDA Paragraph IV framework, the asserted defenses usually cluster around:

• Non-infringement under §271(e)(2): Amneal’s ANDA product does not meet all claim limitations.
• Invalidity under §282: anticipation, obviousness, lack of written description/enablement (depending on patent type), and sometimes indefiniteness.
• Inducement/contributory infringement: if asserted (usually tethered to the ANDA submission and intended label claims).
• Procedural defenses: proper notice, standing, claim limitations tied to the ANDA.

What matters most for the business outcome

• Whether AZURITY asserted only composition/formulation claims or also method-of-use claims. Method-of-use often turns on proposed labeling.
• Whether Amneal filed a section viii statement carve-out (if relevant) that could alter the labeling and thus the method-of-use infringement analysis.

Specific Paragraph IV notice content and asserted defenses cannot be enumerated without access to the complaint, answer, or docket docket-entries text.

Did AZURITY and AMNEAL reach a settlement, and did it affect launch timing?

Answer (how settlements typically structure outcomes): Settlements in Hatch-Waxman cases commonly include:

• dismissal of the infringement claims,
• licensing terms (sometimes for “permitted” launch dates),
• mutual covenants not to sue for a defined period,
• agreement on future design-around parameters,
• payment terms or reverse-payment-like consideration (varies by structure and enforceability).

Business relevance

• Settlement terms often control the “effective exclusivity” window more than patent expiration itself because settlements can include earlier launch carve-outs or later triggers.
• If settlement ties to a patent-by-patent schedule, portfolio planning must match each asserted patent’s expiration and any stipulated trigger.

The prompt provides no settlement docket entry, no dismissal order details, and no consent judgment information, so settlement status and terms cannot be determined.

What FDA regulatory milestone does 3:21-cv-08717 map to: ANDA approval, launch, or labeling changes?

Answer (FDA linkage): The court case is tied to the ANDA’s Paragraph IV notice and planned commercial activity. The controlling FDA/regulatory events include:

• ANDA submission and acceptance,
• approval status (tentative/Final),
• label approval and any carve-outs affecting method-of-use coverage,
• whether the ANDA approval is stayed due to litigation.

Where this becomes actionable

• If method-of-use infringement is at issue, label changes can function as a design-around.
• If formulation/process patents dominate, regulatory labeling changes may not avoid infringement.

Without identifying the AZURITY product and Amneal’s ANDA specifics, this FDA mapping cannot be performed.

Which jurisdictions and courts control enforcement for 3:21-cv-08717?

Answer (jurisdictional scope): The docket number 3:21-cv-08717 indicates the case is filed in a U.S. District Court (federal jurisdiction). Enforcement of infringement judgments is U.S.-wide for the defendant’s conduct governed by the court’s orders, subject to any appellate stay dynamics.

Practical enforcement implications

• Injunction scope can affect U.S. launch even if the underlying patent is also relevant internationally.
• If an appeal is filed, the Federal Circuit’s review can change the enforceability timeline.

The prompt does not supply the district court name, judge, or appellate status.

Key takeaways for litigation strategy and generic entry planning

• This is a Hatch-Waxman-style ANDA patent dispute where AZURITY’s asserted rights depend on which Orange Book patents were litigated and which claims survived early procedural and construction milestones.
• Business timing hinges on court outcomes (invalidity/non-infringement/injunction) and any settlement triggers, not just patent expiration dates.
• The patent type determines the design-around path: formulation and composition typically resist simple labeling changes; method-of-use can be mitigated via label carve-outs.
• Portfolio risk cannot be quantified from the docket identifier alone. A usable risk model requires the asserted patent list, claim construction rulings, and whether the court entered final judgment or a settlement dismissal.

FAQs

1) What court orders most directly affect launch timing in ANDA patent cases like 3:21-cv-08717?
Final judgment (infringement and invalidity), injunction scope, and any appellate or settlement dismissal terms tied to a trigger date.

2) How do method-of-use patents change the infringement analysis in Paragraph IV suits?
They shift infringement toward proposed FDA labeling and indications, so label carve-outs can reduce infringement exposure if they remove the covered use.

3) What evidence usually drives obviousness in formulation/process patent disputes?
Expert testimony, prior-art references, and reproducibility of the claimed formulation properties, such as dissolution or stability parameters.

4) Can a settlement in Hatch-Waxman cases accelerate or delay ANDA launch versus patent expiration?
Yes. Settlements often include trigger dates and permitted launch windows that can supersede the raw patent calendar.

5) What data points should be monitored to assess appellate risk after a trial court decision?
Federal Circuit briefing orders, stays pending appeal, and any remand instructions that alter claim construction or validity findings.

References

1. Hatch-Waxman Framework, 35 U.S.C. §§ 271(e)(2), 282.
2. U.S. patent litigation and Orange Book practice under 21 U.S.C. § 355(j) (Paragraph IV).